United States Influenza Vaccines Market Forecast 2020 - 2027
The United States influenza vaccines market is set to surpass USD 5.1 Billion by 2027.
Key Highlights:
The report comprehends a profound study with size in terms of both value and volume of the US influenza vaccines market. The report delivers a clear understanding of the up-to-date and future growths of the United States influenza vaccines market. The report also discovers a comprehensive investigation of the children and adults vaccinated with influenza vaccines in the United States from 2013 to 2019 and forecasts to 2027. The report also details the latest information about influenza vaccine production, supply, and allocation by major companies in the United States between 2014 – 2015 and 2020 - 2021.
An all-inclusive examination has been done on the pricing, distribution, demand, and effectiveness of the influenza vaccines in the United States. It also provides a deep and in-depth evaluation of the distribution channel and technique of the influenza vaccination in the United States.
Additionally, this up-to-date report describes the latest features reimbursement pattern and offers a clear view of the regulatory framework of the United States influenza vaccines market. Moreover, the report analyses the most recent clinical trials review promising influenza vaccines in clinical development and rapid diagnostic testing for the management of influenza. The report also tracks and analyses competitive developments, including collaboration, merger & acquisition, distribution, exclusive and licensing agreement, new vaccine developments, and R&D activities in the market. The report also delivers an in-depth analysis of evolving market trends, drivers, and restraining forces that influence the growth of the market.
The report also analyses detailed profiles of innovative and leading players with information on business overview, companies’ vaccines portfolio, influenza vaccines market value, and the latest developments.
Other emerging players are making novel technology-based vaccines that are likely to affect the market share during the forecast period. The emerging players are evaluated on various parameters such as business overview, promising vaccines in the clinical development with phase, platform technology, and the latest development.
The Major Companies Dominating this Market for its Products, Services and Continuous Product Developments are:
Key Highlights:
- Influenza vaccines demand is anticipated to increase in the US for 2020 – 2021 Flu Season
- Emergent BioSolutions Signs Contract with Novavax to Manufacture NanoFlu
- Dynavax and Mount Sinai Announce Collaboration to Progress a Universal Influenza Vaccine
- AstraZeneca Ships Flumist Quadrivalent Vaccine in the US for 2020-2021 Flu Season
- Other three companies (Sanofi, GSK and Seqirus) have also Commences Shipping Flu Vaccines in the US for 2020-2021 Flu Season
- The Market Size of the United States Influenza Vaccines Market with Seven Years Forecast
- Analyses the United States Overall Persons Being Vaccinated with Influenza Vaccines with Seven Years Forecast
- Examines the United States Children Being Vaccinated with Influenza Vaccines with Seven Years Forecast
- Scrutinizes the United States Adults Being Vaccinated with Influenza Vaccines with Seven Years Forecast
- Delivers Inclusive Insights on the Latest Pricing Trends and Analysis
- Covers a Complete Analysis of the US Influenza Vaccines Production, Supply, and Allocation (By Companies)
- Delivers a Comprehensive Outline of the US Influenza Vaccines Distribution and Demand
- Studies the Latest Effectiveness of the Influenza Vaccines in the United States
- Thoroughly Assessment of the Rapid Diagnostic Testing for the Management of Influenza
- Meticulously Assesses of the Distribution Channel and Technique of the Influenza Vaccination in the United States
- Detailed Insights into the Regulatory Framework of the United States Influenza Vaccines Market
- Features Reimbursement Patterns of the United States Influenza Vaccines Market
- Tracks Competitive Developments, Approaches, Recent Industry Developments, Mergers & Acquisitions. Collaboration, Distribution, Exclusive and Licensing Agreement
- An Insightful Investigation has been done on Promising Influenza Vaccines in the Clinical Development
- Analyses the Most Recent Clinical Trials of the Influenza Vaccines between 2019 and 2020
- Delivers an In-Depth Analysis of Evolving Market Trends, Drivers and Restraints of the United States Influenza Vaccines Market
- A Comprehensive List of the Key Players Along with the Analysis of their Current Vaccines Portfolios, Promising Vaccines in the Clinical Development, Influenza Vaccines Market Value, and Recent Development
- An Insightful Analysis of the Emerging Players Along with the Analysis of their Promising Vaccines in the Clinical Development, Phase, Platform Technology, and Recent Development
The report comprehends a profound study with size in terms of both value and volume of the US influenza vaccines market. The report delivers a clear understanding of the up-to-date and future growths of the United States influenza vaccines market. The report also discovers a comprehensive investigation of the children and adults vaccinated with influenza vaccines in the United States from 2013 to 2019 and forecasts to 2027. The report also details the latest information about influenza vaccine production, supply, and allocation by major companies in the United States between 2014 – 2015 and 2020 - 2021.
An all-inclusive examination has been done on the pricing, distribution, demand, and effectiveness of the influenza vaccines in the United States. It also provides a deep and in-depth evaluation of the distribution channel and technique of the influenza vaccination in the United States.
Additionally, this up-to-date report describes the latest features reimbursement pattern and offers a clear view of the regulatory framework of the United States influenza vaccines market. Moreover, the report analyses the most recent clinical trials review promising influenza vaccines in clinical development and rapid diagnostic testing for the management of influenza. The report also tracks and analyses competitive developments, including collaboration, merger & acquisition, distribution, exclusive and licensing agreement, new vaccine developments, and R&D activities in the market. The report also delivers an in-depth analysis of evolving market trends, drivers, and restraining forces that influence the growth of the market.
The report also analyses detailed profiles of innovative and leading players with information on business overview, companies’ vaccines portfolio, influenza vaccines market value, and the latest developments.
Other emerging players are making novel technology-based vaccines that are likely to affect the market share during the forecast period. The emerging players are evaluated on various parameters such as business overview, promising vaccines in the clinical development with phase, platform technology, and the latest development.
The Major Companies Dominating this Market for its Products, Services and Continuous Product Developments are:
- Sanofi Pasteur
- GlaxoSmithKline (GSK)
- Seqirus (CSL Limited)
- AstraZeneca
- Novavax
- BiondVax Pharmaceuticals Ltd.
- Medicago
- Moderna Inc
- Pneumagen
- Daiichi–Sankyo
- Altimmune
- FluGen
- Imutex
- What is the current size of the overall influenza vaccines market in the United States?
- How much will this market be worth from 2020 to 2027?
- How many persons being vaccinated with influenza vaccines in the US during 2013 – 2027?
- How effective is influenza (flu) shot for 2020?
- What percentage of the United States do people get the flu vaccine?
- What are the key marketed influenza vaccines available in the United States?
- What are the major drivers of the United States influenza vaccines market?
- What are the major inhibitors of the United States influenza vaccines market?
- What is the reimbursement pattern in the United States influenza vaccines market?
- What is the regulatory framework in the United States influenza vaccines market?
- What are the major deals and agreement happenings in the United States influenza vaccines market?
- What are the upcoming influenza vaccines that will have a significant impact on the market in the future?
- Who are the top market players? What are their happenings, vaccines revenue, current developments, and scenarios?
- Who are the emerging players? What are their happenings, clinical development, platform technology, phase, and current developments?
- How is the market predicted to develop in the future?
1. EXECUTIVE SUMMARY
2. UNITED STATES INFLUENZA VACCINES MARKET SIZE & ANALYSIS (2013 - 2027)
3. UNITED STATES NUMBER OF PERSONS VACCINATED WITH INFLUENZA VACCINES (2013 - 2027)
3.1 Number of Children Vaccinated with Influenza Vaccines
3.2 Number of Adults Vaccinated with Influenza Vaccines
4. KEY DRIVERS AND INHIBITORS OF THE UNITED STATES INFLUENZA VACCINES MARKET
4.1 Market Drivers
4.2 Market Restraints
5. UNITED STATES INFLUENZA VACCINES PRICING TRENDS & ANALYSIS
6. UNITED STATES INFLUENZA VACCINES PRODUCTION, SUPPLY, AND ALLOCATION (BY COMPANIES)
7. UNITED STATES INFLUENZA VACCINES DISTRIBUTION & DEMAND (2010 - 2020)
8. EFFECTIVENESS OF INFLUENZA VACCINES IN THE UNITED STATES (2004 – 2020)
9. RAPID DIAGNOSTIC TESTING FOR THE MANAGEMENT OF INFLUENZA
10. DISTRIBUTION CHANNEL & TECHNIQUE OF INFLUENZA VACCINATION IN THE UNITED STATES
11. REIMBURSEMENT ENVIRONMENT OF THE UNITED STATES INFLUENZA VACCINES MARKET
12. REGULATORY FRAMEWORK OF THE UNITED STATES INFLUENZA VACCINES MARKET
13. MAJOR DEALS AND AGREEMENT HAPPENINGS IN THE INFLUENZA VACCINES MARKET
13.1 Merger & Acquisitions
13.2 Collaboration Deal
13.3 Licensing Agreement
13.4 Exclusive Agreement
13.5 Distribution Agreement
14. PROMISING INFLUENZA VACCINES IN THE CLINICAL DEVELOPMENT
15. INFLUENZA VACCINES CLINICAL TRIAL INSIGHTS BY PHASE, COMPANY & COUNTRY
15.1 Year 2020
15.2 Year 2019
16. KEY PLAYERS ANALYSIS
16.1 Sanofi Pasteur
16.1.1 Business Overview
16.1.2 Influenza Vaccines Portfolio
16.1.3 Influenza Vaccines Sales Value Analysis
16.1.4 Promising Influenza Vaccines in the Clinical Development
16.1.5 Recent Development
16.2 GlaxoSmithKline (GSK)
16.2.1 Business Overview
16.2.2 Influenza Vaccines Portfolio
16.2.3 Influenza Vaccines Sales Value Analysis
16.2.4 Recent Development
16.3 Seqirus
16.3.1 Business Overview
16.3.2 Influenza Vaccines Portfolio
16.3.3 Influenza Vaccines Sales Value Analysis
16.3.4 Promising Influenza Vaccines in the Clinical Development
16.3.5 Recent Development
16.4 AstraZeneca
16.4.1 Business Overview
16.4.2 Influenza Vaccines Portfolio
16.4.3 Influenza Vaccines Sales Value Analysis
16.4.4 Recent Development
17. EMERGING PLAYERS ANALYSIS
17.1 Novavax
17.1.1 Business Overview
17.1.2 Promising Influenza Vaccines in the Clinical Development
17.1.3 Recent Development
17.2 BiondVax Pharmaceuticals Ltd.
17.2.1 Business Overview
17.2.2 Promising Influenza Vaccines in the Clinical Development
17.2.3 Recent Development
17.3 Medicago
17.3.1 Business Overview
17.3.2 Promising Influenza Vaccines in the Clinical Development
17.3.3 Recent Development
17.4 Moderna Inc
17.4.1 Business Overview
17.4.2 Promising Influenza Vaccines in the Clinical Development
17.4.3 Recent Development
17.5 Pneumagen
17.5.1 Business Overview
17.5.2 Promising Influenza Vaccines in the Clinical Development
17.5.3 Recent Development
17.6 Altimmune
17.6.1 Business Overview
17.6.2 Promising Influenza Vaccines in the Clinical Development
17.6.3 Recent Development
17.7 Daiichi Sankyo
17.7.1 Business Overview
17.7.2 Promising Influenza Vaccines in the Clinical Development
17.7.3 Recent Development
17.8 FluGen
17.8.1 Business Overview
17.8.2 Promising Influenza Vaccines in the Clinical Development
17.8.3 Recent Development
17.9 Imutex
17.9.1 Business Overview
17.9.2 Promising Influenza Vaccines in the Clinical Development
17.9.3 Recent Development
2. UNITED STATES INFLUENZA VACCINES MARKET SIZE & ANALYSIS (2013 - 2027)
3. UNITED STATES NUMBER OF PERSONS VACCINATED WITH INFLUENZA VACCINES (2013 - 2027)
3.1 Number of Children Vaccinated with Influenza Vaccines
3.2 Number of Adults Vaccinated with Influenza Vaccines
4. KEY DRIVERS AND INHIBITORS OF THE UNITED STATES INFLUENZA VACCINES MARKET
4.1 Market Drivers
4.2 Market Restraints
5. UNITED STATES INFLUENZA VACCINES PRICING TRENDS & ANALYSIS
6. UNITED STATES INFLUENZA VACCINES PRODUCTION, SUPPLY, AND ALLOCATION (BY COMPANIES)
7. UNITED STATES INFLUENZA VACCINES DISTRIBUTION & DEMAND (2010 - 2020)
8. EFFECTIVENESS OF INFLUENZA VACCINES IN THE UNITED STATES (2004 – 2020)
9. RAPID DIAGNOSTIC TESTING FOR THE MANAGEMENT OF INFLUENZA
10. DISTRIBUTION CHANNEL & TECHNIQUE OF INFLUENZA VACCINATION IN THE UNITED STATES
11. REIMBURSEMENT ENVIRONMENT OF THE UNITED STATES INFLUENZA VACCINES MARKET
12. REGULATORY FRAMEWORK OF THE UNITED STATES INFLUENZA VACCINES MARKET
13. MAJOR DEALS AND AGREEMENT HAPPENINGS IN THE INFLUENZA VACCINES MARKET
13.1 Merger & Acquisitions
13.2 Collaboration Deal
13.3 Licensing Agreement
13.4 Exclusive Agreement
13.5 Distribution Agreement
14. PROMISING INFLUENZA VACCINES IN THE CLINICAL DEVELOPMENT
15. INFLUENZA VACCINES CLINICAL TRIAL INSIGHTS BY PHASE, COMPANY & COUNTRY
15.1 Year 2020
15.2 Year 2019
16. KEY PLAYERS ANALYSIS
16.1 Sanofi Pasteur
16.1.1 Business Overview
16.1.2 Influenza Vaccines Portfolio
16.1.3 Influenza Vaccines Sales Value Analysis
16.1.4 Promising Influenza Vaccines in the Clinical Development
16.1.5 Recent Development
16.2 GlaxoSmithKline (GSK)
16.2.1 Business Overview
16.2.2 Influenza Vaccines Portfolio
16.2.3 Influenza Vaccines Sales Value Analysis
16.2.4 Recent Development
16.3 Seqirus
16.3.1 Business Overview
16.3.2 Influenza Vaccines Portfolio
16.3.3 Influenza Vaccines Sales Value Analysis
16.3.4 Promising Influenza Vaccines in the Clinical Development
16.3.5 Recent Development
16.4 AstraZeneca
16.4.1 Business Overview
16.4.2 Influenza Vaccines Portfolio
16.4.3 Influenza Vaccines Sales Value Analysis
16.4.4 Recent Development
17. EMERGING PLAYERS ANALYSIS
17.1 Novavax
17.1.1 Business Overview
17.1.2 Promising Influenza Vaccines in the Clinical Development
17.1.3 Recent Development
17.2 BiondVax Pharmaceuticals Ltd.
17.2.1 Business Overview
17.2.2 Promising Influenza Vaccines in the Clinical Development
17.2.3 Recent Development
17.3 Medicago
17.3.1 Business Overview
17.3.2 Promising Influenza Vaccines in the Clinical Development
17.3.3 Recent Development
17.4 Moderna Inc
17.4.1 Business Overview
17.4.2 Promising Influenza Vaccines in the Clinical Development
17.4.3 Recent Development
17.5 Pneumagen
17.5.1 Business Overview
17.5.2 Promising Influenza Vaccines in the Clinical Development
17.5.3 Recent Development
17.6 Altimmune
17.6.1 Business Overview
17.6.2 Promising Influenza Vaccines in the Clinical Development
17.6.3 Recent Development
17.7 Daiichi Sankyo
17.7.1 Business Overview
17.7.2 Promising Influenza Vaccines in the Clinical Development
17.7.3 Recent Development
17.8 FluGen
17.8.1 Business Overview
17.8.2 Promising Influenza Vaccines in the Clinical Development
17.8.3 Recent Development
17.9 Imutex
17.9.1 Business Overview
17.9.2 Promising Influenza Vaccines in the Clinical Development
17.9.3 Recent Development
LIST OF TABLES:
Table 5–1: United States Pediatric Influenza Vaccines Price, 2020 – 2021
Table 5–2: United States Adult Influenza Vaccine Price, 2020 – 2021
Table 6–1: United States Influenza Vaccines Production, Supply, and Allocation
Table 7–1: Total Percentage of Influenza Vaccines Released by Week, 2019 – 2020
Table 7–2: Total Percentage of Influenza Vaccines Released by Week,2018 – 2019
Table 7–3: Total Percentage of Influenza Vaccines Released by Week,2017 – 2018
Table 7–4: Total Percentage of Influenza Vaccines Released by Week,2016 – 2017
Table 7–5: Total Percentage of Influenza Vaccines Released by Week,2015 – 2016
Table 7–6: Total Percentage of Influenza Vaccines Released by Week,2014 – 2015
Table 8–1: Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2004 – 2020
Table 9–1: Influenza Virus Testing Methods
Table 10–1: Distribution of Influenza Vaccination
Table 12–1: United States Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 13–1: Merger & Acquisitions in the Influenza Vaccines Market
Table 13–2: Collaboration Deal in the Influenza Vaccines Market
Table 13–3: Licensing Agreement in the Influenza Vaccines Market
Table 13–4: Exclusive Agreement in the Influenza Vaccines Market
Table 13–5: Distribution Agreement in the Influenza Vaccines Market
Table 14–1: BiondVax Pharmaceuticals Ltd. – Clinical Trials
Table 16–1: Sanofi Pasteur Promising Influenza Vaccines in the Clinical Development
Table 16–2: Seqirus Promising Influenza Vaccines in the Clinical Development
Table 17–1: Novavax Promising Influenza Vaccines in the Clinical Development
Table 17–2: Biondvax Promising Influenza Vaccines in the Clinical Development
Table 17–3: Medicago Promising Influenza Vaccines in the Clinical Development
Table 17–4: Moderna Promising Influenza Vaccines in the Clinical Development
Table 17–5: Pneumagen Promising Influenza Vaccines in the Clinical Development
Table 17–6: Altimmune Promising Influenza Vaccines in the Clinical Development
Table 17–7: Daiichi Sankyo Promising Influenza Vaccines in the Clinical Development
Table 17–8: FluGen Promising Influenza Vaccines in the Clinical Development
Table 17–9: Imutex Promising Influenza Vaccines in the Clinical Development
Table 5–1: United States Pediatric Influenza Vaccines Price, 2020 – 2021
Table 5–2: United States Adult Influenza Vaccine Price, 2020 – 2021
Table 6–1: United States Influenza Vaccines Production, Supply, and Allocation
Table 7–1: Total Percentage of Influenza Vaccines Released by Week, 2019 – 2020
Table 7–2: Total Percentage of Influenza Vaccines Released by Week,2018 – 2019
Table 7–3: Total Percentage of Influenza Vaccines Released by Week,2017 – 2018
Table 7–4: Total Percentage of Influenza Vaccines Released by Week,2016 – 2017
Table 7–5: Total Percentage of Influenza Vaccines Released by Week,2015 – 2016
Table 7–6: Total Percentage of Influenza Vaccines Released by Week,2014 – 2015
Table 8–1: Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2004 – 2020
Table 9–1: Influenza Virus Testing Methods
Table 10–1: Distribution of Influenza Vaccination
Table 12–1: United States Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 13–1: Merger & Acquisitions in the Influenza Vaccines Market
Table 13–2: Collaboration Deal in the Influenza Vaccines Market
Table 13–3: Licensing Agreement in the Influenza Vaccines Market
Table 13–4: Exclusive Agreement in the Influenza Vaccines Market
Table 13–5: Distribution Agreement in the Influenza Vaccines Market
Table 14–1: BiondVax Pharmaceuticals Ltd. – Clinical Trials
Table 16–1: Sanofi Pasteur Promising Influenza Vaccines in the Clinical Development
Table 16–2: Seqirus Promising Influenza Vaccines in the Clinical Development
Table 17–1: Novavax Promising Influenza Vaccines in the Clinical Development
Table 17–2: Biondvax Promising Influenza Vaccines in the Clinical Development
Table 17–3: Medicago Promising Influenza Vaccines in the Clinical Development
Table 17–4: Moderna Promising Influenza Vaccines in the Clinical Development
Table 17–5: Pneumagen Promising Influenza Vaccines in the Clinical Development
Table 17–6: Altimmune Promising Influenza Vaccines in the Clinical Development
Table 17–7: Daiichi Sankyo Promising Influenza Vaccines in the Clinical Development
Table 17–8: FluGen Promising Influenza Vaccines in the Clinical Development
Table 17–9: Imutex Promising Influenza Vaccines in the Clinical Development
LIST OF FIGURES:
Figure 2–1: United States Influenza Vaccines Market (Million US$),2013 – 2019
Figure 2–2: United States Influenza Vaccines Market Forecast (Million US$),2020 – 2027
Figure 3–1: United States Total Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2013 – 2019
Figure 3–2: United States Total Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 3–3: United States Number of Children Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 3–4: United States Number of Children Vaccinated with Influenza Vaccines Forecast (Thousand),2020 – 2027
Figure 3–5: United States Number of Adults Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 3–6: United States Number of Adults Vaccinated with Influenza Vaccines Forecast (Thousand),2020 – 2027
Figure 7–1: United States Influenza Vaccine Doses Distributed, By Season (Million),2010 – 2020
Figure 10–1: United States Place of Influenza Vaccination for Children and Adults (Percent),2018 - 2019
Figure 16–1: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US$),2013 – 2019
Figure 16–2: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US$),2020 – 2027
Figure 16–3: GSK Influenza Vaccines Net Sales Value (Million US$),2013 – 2019
Figure 16–4: GSK Influenza Vaccines Net Sales Value Forecast (Million US$),2020 – 2027
Figure 16–5: Seqirus Influenza Vaccines Net Sales Value (Million US$),2015 – 2019
Figure 16–6: Seqirus Influenza Vaccines Net Sales Value Forecast (Million US$),2020 – 2027
Figure 16–7: AstraZeneca Influenza Vaccines Net Sales Value (Million US$),2013 – 2019
Figure 16–8: AstraZeneca Influenza Vaccines Net Sales Value Forecast (Million US$),2020 – 2027
Figure 2–1: United States Influenza Vaccines Market (Million US$),2013 – 2019
Figure 2–2: United States Influenza Vaccines Market Forecast (Million US$),2020 – 2027
Figure 3–1: United States Total Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2013 – 2019
Figure 3–2: United States Total Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 3–3: United States Number of Children Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 3–4: United States Number of Children Vaccinated with Influenza Vaccines Forecast (Thousand),2020 – 2027
Figure 3–5: United States Number of Adults Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 3–6: United States Number of Adults Vaccinated with Influenza Vaccines Forecast (Thousand),2020 – 2027
Figure 7–1: United States Influenza Vaccine Doses Distributed, By Season (Million),2010 – 2020
Figure 10–1: United States Place of Influenza Vaccination for Children and Adults (Percent),2018 - 2019
Figure 16–1: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US$),2013 – 2019
Figure 16–2: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US$),2020 – 2027
Figure 16–3: GSK Influenza Vaccines Net Sales Value (Million US$),2013 – 2019
Figure 16–4: GSK Influenza Vaccines Net Sales Value Forecast (Million US$),2020 – 2027
Figure 16–5: Seqirus Influenza Vaccines Net Sales Value (Million US$),2015 – 2019
Figure 16–6: Seqirus Influenza Vaccines Net Sales Value Forecast (Million US$),2020 – 2027
Figure 16–7: AstraZeneca Influenza Vaccines Net Sales Value (Million US$),2013 – 2019
Figure 16–8: AstraZeneca Influenza Vaccines Net Sales Value Forecast (Million US$),2020 – 2027
